Virtus ETF Advisers’s Belite Bio BLTE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,122
Closed -$70.8K 474
2024
Q4
$70.8K Sell
1,122
-721
-39% -$47.5K 0.03% 369
2024
Q3
$86.4K Buy
1,843
+36
+2% +$1.75K 0.04% 398
2024
Q2
$82.5K Sell
1,807
-152
-8% -$6.58K 0.04% 392
2024
Q1
$75.2K Sell
1,959
-137
-7% -$6.13K 0.04% 400
2023
Q4
$95.9K Buy
+2,096
New +$80.6K 0.06% 378

Other funds holding BLTE

Virtus ETF Advisers's BLTE Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Belite Bio (BLTE) in Q1 2025, closing a stake of 1,122 shares — an estimated $70.8K sold.

Virtus ETF Advisers first reported a position in BLTE in Q4 2023 and held it in 5 quarters. The position peaked at $95.9K in Q4 2023. 18 funds tracked by Wall St. Rank hold BLTE as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Belite Bio position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,122 Belite Bio shares in Q1 2025, an estimated $70.8K.
  • Virtus ETF Advisers first reported a position in Belite Bio in Q4 2023 and held it in 5 quarters.
  • Virtus ETF Advisers's Belite Bio position peaked at $95.9K in Q4 2023.
  • 18 funds tracked by Wall St. Rank held Belite Bio as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.